Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent

LONDON, Oct. 20 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the "Zamore Design Rules."  European patent number 1 633 890 titled "Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi" was published today in the European Patent Bulletin.  The European patent covers various breakthrough structural modification methods and compositions which Silence believes are fundamental for the development and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this comprehensive patent in Europe is a significant milestone for Silence in our ongoing effort to build one of the world's leading RNAi intellectual property positions.  We have consistently built a strong IP estate around the Zamore technology in the U.S. and have now extended our global coverage to Europe with the granting of this critical patent," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We have often stated our belief that the 'Zamore Design Rules' represent significant IP to enable the process of bringing effective RNAi therapeutics to market.  With this latest patent grant from the EPO, we are excited to be able to offer potential collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent's method and composition claims include:

  • Methods of enhancing the ability of an antisense strand of an RNAi agent to act as a guide strand
  • RNAi or siRNA agents for enhancing silencing of a target mRNA in a subject
  • Compositions for siRNA duplexes include pre-miRNA and shRNA and vectors to perform the methods described herein

Silence owns exclusive licenses to the "Zamore Design Rule" patent families in the human healthcare field from the University of Massachusetts Medical School.  These patent families disclose various efficacy-enhancing methods and structural elements for RNAi therapeutics, informally known as the "Zamore Design Rules" and are based on the seminal research of Phillip D. Zamore, Ph.D. at the University of Massachusetts Medical School.  Dr. Zamore is a Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical School.  He also serves as co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School.  Silence expects additional patent issuances related to the Zamore portfolio.  

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects a number of additional valuable RNAi patents to be issued in both the United States and Europe.  At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors

About Silence Therapeutics plc (

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the "Zamore Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November ... NeuroRehabilitation (ECNR) in Vienna, Austria ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> NovaVision, a wholly owned subsidiary of Vycor Medical, ... version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult stem ... subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional ... Office of the Chief Scientist (OCS). This grant, the second ... for 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
Breaking Biology News(10 mins):